Physician profile
Firas M Rahhal
NPI 1881658615
$263,814.99
in general payments reported to CMS, 2019-2025
31 companies · $117K in 2025
The $117K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,688 · 2020: $14K · 2021: $44K · 2022: $1,460 · 2023: $37K · 2024: $44K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $172K · Honoraria: $15K · Food and Beverage: $6,882 · Travel and Lodging: $3,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $171,762.00 |
| Honoraria | $15,050.00 |
| Food and Beverage | $6,881.56 |
| Travel and Lodging | $3,605.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beaver-Visitec International, INC. | $112,358.00 | 2019-2025 | |
| Alcon Vision LLC | $88,289.16 | 2019-2025 | Constellation, Unity, Systane |
| Alcon Research LLC | $18,146.81 | 2021-2024 | |
| Coherus Oncology, INC. | $15,723.37 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15,459.27 | 2024-2025 | |
| Astellas Pharma US INC | $3,198.21 | 2023-2024 | Izervay |
| Carl Zeiss Meditec, INC. | $2,836.10 | 2019-2020 | |
| Roche Tcrc, INC. | $1,847.51 | 2019 | |
| Apellis Pharmaceuticals, INC. | $1,010.50 | 2022-2025 | Syfovre |
| Alimera Sciences, INC. | $774.98 | 2019-2020 | |
| Abbvie INC. | $592.44 | 2022-2025 | |
| Genentech USA, INC. | $518.21 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $513.75 | 2022-2025 | Eylea Hd, Eylea |
| Sandoz INC. | $280.53 | 2024 | Cimerli |
| Eyepoint US, INC. | $271.74 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $265.55 | 2024 | |
| Amgen INC. | $265.50 | 2024-2025 | Lumakras |
| Allergan, INC. | $247.17 | 2020-2022 | |
| Ocular Therapeutix, INC. | $215.53 | 2025 | Dextenza |
| Mallinckrodt Hospital Products INC. | $197.58 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $182.96 | 2022 | |
| Bausch & Lomb Americas INC. | $150.46 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $101.63 | 2021 | |
| Genentech, INC. | $77.49 | 2019 | |
| Biogen, INC. | $66.34 | 2022-2024 | Byooviz |
| Baxter Healthcare | $58.38 | 2024 | Preveleak |
| Oculus Surgical INC. | $23.42 | 2025 | |
| Glaxosmithkline, LLC. | $17.51 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Rahhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.